Mark Cuban sees potential in executive order on pharma pricing
@mcuban: Cuban on pharma pricing
In a recent tweet, entrepreneur and investor Mark Cuban commented on a new executive order regarding pharmaceutical pricing. He suggested that if brand-name pharmaceutical companies begin selling their products at prices even slightly higher than those offered to Pharmacy Benefit Managers (PBMs), the market could see significant changes.
Cuban further implied that such pricing would allow his venture, Cost Plus Drugs, to offer competitive cash pricing close to the intended targets of the executive order. This approach is compared to past reforms on hospital pricing under former President Trump's administration.
The executive order under discussion aims to bring transparency and fairness to drug pricing, but there is skepticism about whether pharmaceutical companies will adjust their pricing strategies, given their complicated relationships with PBMs.
Mark Cuban's perspective, as the owner of Cost Plus Drugs, offers insight into potential shifts in drug pricing and how it might lead to more affordable medication for consumers.
Loading...
